The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Exploratory analysis of biomarkers of response to durvalumab in advanced HER2-negative oesophago-gastric adenocarcinoma within a phase 2 clinical trial.
 
Hazel Lote
No Relationships to Disclose
 
Eleftheria Giota
No Relationships to Disclose
 
Caroline Fong
Honoraria - Bristol-Myers Squibb
 
Anderley Gordon
No Relationships to Disclose
 
Ruwaida Begum
No Relationships to Disclose
 
Laura Satchwell
No Relationships to Disclose
 
Shannon Kidd
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Lilly (Inst)
 
Susan Cromarty
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Lilly (Inst)
 
Charlotte Victoria Fribbens
No Relationships to Disclose
 
Naureen Starling
Honoraria - Amgen; AstraZeneca; BMS; BMS; GlaxoSmithKline; GlaxoSmithKline; Lilly; Lilly; Merck; Merck Serono; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Novartis; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre; Seagen; SERVIER; SERVIER; SERVIER; SERVIER
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; GlaxoSmithKline; Janssen; MSD; MSD Oncology; MSD Oncology; Novartis Pharmaceuticals UK Ltd.; Pfizer; Seagen; SERVIER
Research Funding - AstraZeneca (Inst); BMS (Inst); Guardant Health (Inst); Merck Serono (Inst); Pfizer/EMD Serono (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline; Guardant Health; MSD Oncology; SERVIER
(OPTIONAL) Uncompensated Relationships - Guardant Health
 
Sheela Rao
Honoraria - Bayer; Incyte; Merck Serono; Servier (I)
Consulting or Advisory Role - AstraZeneca; Bayer
Travel, Accommodations, Expenses - SERVIER
 
Ian Chau
Honoraria - Bristol-Myers Squibb; Eisai; Lilly; Novartis; Roche/Genentech; SERVIER
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BioNTech SE; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Eisai; GlaxoSmithKline; Lilly; Merck Serono; MSD Oncology; OncXerna Therapeutics; Roche/Genentech; Seagen; SERVIER; Sotio; Taiho Oncology; Turning Point Therapeutics
Research Funding - Janssen-Cilag (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - BMS; SERVIER
 
David Cunningham
Stock and Other Ownership Interests - OVIBIO
Consulting or Advisory Role - OVIBIO
Research Funding - 4SC (Inst); Bayer (Inst); Clovis Oncology (Inst); Leap Oncology (Inst); Lilly (Inst); MedImmune (Inst); Roche (Inst)
 
Luis Zapata
No Relationships to Disclose